Author

Yusuke Satoh

Hokkaido UniversityORCID 0009-0001-5237-7403Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:Drosophila· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

Kotaro MatobaiD· 2 shared Masahiro SonoshitaiD· 2 shared Shigeki JiniD· 2 shared Tomoyoshi SogaiD· 2 shared Alexander TyakhtiD· 1 shared Atsushi EnomotoiD· 1 shared Atsushi MasamuneiD· 1 shared Chihiro KamijoiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Kotaro MatobaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Co-targeting an AMPK--MAPK axis reprograms CAFs and suppresses PDAC

Ryodai Yamamura, Yusuke Satoh, Junki Fukuda, Taku Kimura, Takuya Otsuka, Sho Sekiya, Taiga Hirata, Soichiro Hata, Reo Sato, Chihiro Kamijo, Takuya Moriguchi, Shinya Kosuge, Takuya Kato, Yuya Urano, Kanako C. Hatanaka, , Masahiro Sonoshita

This study shows that targeting the AMPK-MAPK axis in cancer-associated fibroblasts suppresses PDAC growth in fly and mouse models by restoring AMPK activity and inhibiting fibroblast activation.

bioRxiv · Mar 18, 2026 · PreprintCancer Biology

Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer

Takako Ooshio, Yusuke Satoh, Hui Jiang, Tongwei Liu, Kiyonaga Fujii, Takamasa Ishikawa, Kaori Igarashi, Kaori Saitoh, Keiko Kato, Tetsuo Mashima, Shigeki Jin, Kotaro Matoba, Matthias Mack, Tsuyoshi Osawa, Hiroyuki Seimiya, , Masahiro Sonoshita

The paper identifies dual targeting of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer by showing synergistic suppression of PDAC xenograft growth.

bioRxiv · Oct 23, 2024 · PreprintCancer Biology